Search results
Results from the WOW.Com Content Network
Robert K. Naviaux (born in 1956) is an American physician-scientist who specializes in mitochondrial medicine and complex chronic disorders. He discovered the cause of Alpers syndrome, [1] [2] and was part of the team that reported the first mitochondrial DNA (mtDNA) mutation to cause genetic forms of autism. [3]
The prevalence estimates of mitochondrial disease and dysfunction across studies ranging from about 5 to 80%. This may be, in part, due to the unclear distinction between mitochondrial disease and dysfunction. Mitochondrial diseases are difficult to diagnose and have become better known and detected.
Richard Eugene Frye is an American autism researcher and associate professor at Arizona Children's Hospital in Phoenix, and formerly of the University of Arkansas for Medical Sciences's department of pediatrics, [1] as well as the Director of the Autism Multispecialty Clinic at Arkansas Children’s Hospital. [2]
Treatment of dysautonomia can be difficult; since it is made up of many different symptoms, a combination of drug therapies is often required to manage individual symptomatic complaints. In the case of autoimmune neuropathy, treatment with immunomodulatory therapies is done. If diabetes mellitus is the cause, control of blood glucose is ...
Mitochondrial DNA depletion syndrome (MDS or MDDS), or Alper's disease, is any of a group of autosomal recessive disorders that cause a significant drop in mitochondrial DNA in affected tissues. Symptoms can be any combination of myopathic , hepatopathic , or encephalomyopathic . [ 1 ]
The amygdala, cerebellum, and many other brain regions have been implicated in autism. [15]Unlike some brain disorders which have clear molecular hallmarks that can be observed in every affected individual, such as Alzheimer's disease or Parkinson's disease, autism does not have a unifying mechanism at the molecular, cellular, or systems level.
Rossignol's best-known paper is a clinical trial of HBOT published in 2009, which received widespread media attention. [12] [18] [19] Critics of this research include Steven Novella, who has noted that Rossignol provides HBOT in his clinical practice and therefore "stands to gain personally if its effectiveness is proven."
Angelman syndrome, autism, cerebral palsy, childhood disintegrative disorder, various neurodegenerative disorders [6] Treatment: Special education, physiotherapy, braces [5] Medication: Anticonvulsants [5] Prognosis: Life expectancy for many is middle age. [5] Frequency: 1 in 8,500 females [4] Lethal in males, with rare exceptions.